SlideShare a Scribd company logo
1 of 21
Download to read offline
Aeha muller 2
Clinical Identification of
Vulnerable Patients and Plaques
Screen the
General
Population
By
Conventional
Risk Factors
(Age,
Gender,
FH,
etc)
Vulnerable
Patients
by
blood
test
Vulnerable
Patients
and
?Vulnerable
Plaques by
Non-
invasive
assessment
Plaque
Vulnerability
Index
by
Invasive
Assessment
ACS and Stable Angina
Patients
“Soft Plaque” on
Contrast-enhanced EBCT
Dr. John Rumberger
Non-invasive CT and MR for VP
…. although there is much discussed
on soft versus hard plaque – the
characterization of any “soft” plaque
as one that is potentially
“vulnerable” remains moot.
Dr. John Rumberger
Presumably Vulnerable Plaques Discovered in 6 Autopsy Specimens
Disrupted Coronary Artery Plaques in 6 Autopsy Specimens
Prevalence of Thin-capped Fibroatheromas (TCFAs) and
Disrupted Plaques in 50 Hearts Examined at Autopsy
NUMBER OF
HEARTS
NUMBER OF
TCFAs
NUMBER OF DPs
32 0 0
4 1 0
2 1 1
3 2 0
1 2 3
1 3 0
1 3 1
1 4 0
1 5 3
4 1 0
From approximately 3000 slides, 0.5% showed DPs and 1 % TCFAs.
Unpublished data, InfraRedx
TCFA & DP Frequency
Frequency of TCFAs & DPs in Individual Patients
(N=50 patients & 3599 spots examined)
0
5
10
15
20
0 1 2 3 4 5 6 7 8
# TCFAs & DPs
#Patients
Thermography
intravascular
MR
Optical Coherence Tomography
Angioscopy
Near IR
Catheter-based Detection of
Vulnerable Plaque
IVUS,
VH
Elastog
raphy
JTS
Nuclear
Image Interpretation
The Volcano IVUS Program
• In-vivo characterization of plaque composition via advanced
spectral analysis
Pending 510(K) review – not available in the United States
Volcano IVUS – Program Goals
Re-Thinking IVUS…
• Speeding the IVUS procedure
• Improving ease of image
interpretation
• Improving consistency of image
interpretation
• Understanding benefit of more
information on plaque
composition
– during PCI
– for risk stratifying lesions and
patients
Pending 510(K) review – not available in the United States
Volcano IVUS – Confirming Feasibility
in a Clinical Setting
Repeatability / Reproducibility (J. Margolis, Miami)
Miami_AA_ROI1_RCA1
0
0.5
1
1.5
2
2.5
3
3.5
4
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57
Frame NumberCSA(mm^2)
Lipid Core Cross-Sectional Area
Fibro-Lipidic Cross-Sectional Area
Fibrous Cross-Sectional Area
Calcified Cross-Sectional Area
Distal Proximal
Miami_AA_ROI1_RCA2
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57
Frame Number
CSA(mm^2)
Lipid Core Cross-Sectional Area
Fibro-Lipidic Cross-Sectional Area
Fibrous Cross-Sectional Area
Calcified Cross-Sectional Area
Distal Proximal
1st Pull-Back
Same Catheter, 2nd Pull-Back
One catheter, two runs
Pending 510(K) review – not available in the United States


SOFT
HARD
IVUS-based Intravascular
Palpography
Investigational Use Only – Not Available for
Sale in the United States
Temperature heterogeneity over the surface of
an endartherectomized carotid plaque
Casscells W et al. Lancet. 1996;347:1447-51
OCT of Disrupted CoronaryPlaque
in a Living Patient MI
Rupture Site, In Vivo
C
L
L
L
Jang, Bouma, Tearney et al, CIMIT
Intravascular MRI CatheterIntravascular MRI Catheter
NC
NCMagnet
Coil
Luminal Zone
Mural Zone
 Catheter based real-time MRI - No external magnets
 High sensitivity & specificity for differentiating:
 Fibrous tissue
 Lipid rich necrotic core
 Calcium
 Thrombus (next generation) Virmani et al, JACC 2004 (Submitted)
Presented by RL Wilensky @ TCT 2004
Over 18 patients studied by
Dr. Hennen – No AE
NIR Spectroscopy for VP Detection
• NIR spectroscopy is a well-validated method
frequently used to assess chemical composition.
• Laser, fiber-optic, and chemometric technologies
make intra-coronary use feasible.
• 3.2Fr IVUS-like rapid-exchange coronary catheter
• Can scan artery through blood
• 20 msec spectra acquisition
• Identifies chemical composition of vessel wall
– TCFA sensitivity and specificity > 85% ex vivo
– TCFA surrogates detected in phantom
Natural History Study of Detection Vulnerable Plaque
1000 patients
with ACS
undergoing
PTCA/
Stenting
Vulnerability Detector
100
Patients
with
suspected
VP
900
Patients
without
suspectedV
P
1 yr F.U.
MI
SCD
Prospect StudyProspect Study
PI, Dr. Gregg StonePI, Dr. Gregg Stone
Guidant, VolcanoGuidant, Volcano
3-vessel imaging post PCI3-vessel imaging post PCI
Angiography (QCA of entire coronary tree)Angiography (QCA of entire coronary tree)
IVUSIVUS
Virtual histologyVirtual histology
PalpographyPalpography
± Thermography (EU only)± Thermography (EU only)
F/U: 1 mo, 6 mo, 1 yrF/U: 1 mo, 6 mo, 1 yr
2 yr,2 yr, ±±3-5 yr3-5 yr
(event driven)(event driven) Repeat imagingRepeat imaging
in pts with eventsin pts with events
Meds recMeds rec
AspirinAspirin
Plavix 1yrPlavix 1yr
StatinStatin
1-year MACE (adjudicated to non-culprit lsn)1-year MACE (adjudicated to non-culprit lsn)
-- Cardiac deathCardiac death
-- Cardiac arrestCardiac arrest
-- Rehospitalization for ACSRehospitalization for ACS
-- Myocardial infarctionMyocardial infarction
-- Clinically driven revascularizationClinically driven revascularization
Procedural Success and Imaging SafetyProcedural Success and Imaging Safety
Ability to complete the protocol-specifiedAbility to complete the protocol-specified
imaging procedures w/o imaging deviceimaging procedures w/o imaging device
related complicationsrelated complications
PROSPECT:PROSPECT: Primary endpointsPrimary endpoints
1 year Follow-up for
Cardiac Events: MI, SCD, UA
Vulnerability Map
of the Human Coronary Artery

More Related Content

What's hot

Ipsilateral carotid artery
Ipsilateral carotid arteryIpsilateral carotid artery
Ipsilateral carotid arteryEmily Wyse
 
Combined Reporter Gene PET And Iron Oxide MRI
Combined Reporter Gene PET And Iron Oxide MRICombined Reporter Gene PET And Iron Oxide MRI
Combined Reporter Gene PET And Iron Oxide MRIadamsh
 
Massive transudative pleural effusion due to CSF fistula – A case report
Massive transudative pleural effusion due to CSF fistula – A case reportMassive transudative pleural effusion due to CSF fistula – A case report
Massive transudative pleural effusion due to CSF fistula – A case reportApollo Hospitals
 

What's hot (19)

Gamida cell ppt_english_5-5-2010
Gamida cell ppt_english_5-5-2010Gamida cell ppt_english_5-5-2010
Gamida cell ppt_english_5-5-2010
 
121 non invasive imaging of coronary arteries
121 non invasive imaging of coronary arteries121 non invasive imaging of coronary arteries
121 non invasive imaging of coronary arteries
 
Detection of vulnerable atherosclerotic plaques by nis
Detection of vulnerable atherosclerotic plaques by nisDetection of vulnerable atherosclerotic plaques by nis
Detection of vulnerable atherosclerotic plaques by nis
 
Deteection of vulnerable atherosclerotic plaque by nis
Deteection of vulnerable atherosclerotic plaque by nisDeteection of vulnerable atherosclerotic plaque by nis
Deteection of vulnerable atherosclerotic plaque by nis
 
Moreno.nir vp.org acc02
Moreno.nir vp.org acc02Moreno.nir vp.org acc02
Moreno.nir vp.org acc02
 
Detection of vulnerable plaque by nis
Detection of vulnerable plaque by nisDetection of vulnerable plaque by nis
Detection of vulnerable plaque by nis
 
Ipsilateral carotid artery
Ipsilateral carotid arteryIpsilateral carotid artery
Ipsilateral carotid artery
 
For print vulnerable patient slides
For print  vulnerable patient slidesFor print  vulnerable patient slides
For print vulnerable patient slides
 
Tct recognition of vulnerable plaque guidelines
Tct recognition of vulnerable plaque guidelines Tct recognition of vulnerable plaque guidelines
Tct recognition of vulnerable plaque guidelines
 
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
 
Vascular interventions atalar- johns hopkins
Vascular interventions  atalar- johns hopkinsVascular interventions  atalar- johns hopkins
Vascular interventions atalar- johns hopkins
 
Vascular interventions
Vascular interventionsVascular interventions
Vascular interventions
 
Atalar
AtalarAtalar
Atalar
 
Combined Reporter Gene PET And Iron Oxide MRI
Combined Reporter Gene PET And Iron Oxide MRICombined Reporter Gene PET And Iron Oxide MRI
Combined Reporter Gene PET And Iron Oxide MRI
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable plaque overview
 
Actual trends in applied science
Actual trends in applied scienceActual trends in applied science
Actual trends in applied science
 
Massive transudative pleural effusion due to CSF fistula – A case report
Massive transudative pleural effusion due to CSF fistula – A case reportMassive transudative pleural effusion due to CSF fistula – A case report
Massive transudative pleural effusion due to CSF fistula – A case report
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
 
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vulnerable (thrombogenic blood
 

Viewers also liked

Viewers also liked (18)

082 smoking and plaque inflammation
082 smoking and plaque inflammation082 smoking and plaque inflammation
082 smoking and plaque inflammation
 
3rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 13rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 1
 
Autoimmune disease
Autoimmune diseaseAutoimmune disease
Autoimmune disease
 
150 sudden pathology of sudden cardiac death
150 sudden pathology of sudden cardiac death150 sudden pathology of sudden cardiac death
150 sudden pathology of sudden cardiac death
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
 
130 mri assessment of human atherosclerotic disease
130 mri assessment of human atherosclerotic disease130 mri assessment of human atherosclerotic disease
130 mri assessment of human atherosclerotic disease
 
245 mri scanner
245 mri scanner245 mri scanner
245 mri scanner
 
Mr contrast agents for vp imaging philip graham
Mr contrast agents for vp imaging  philip grahamMr contrast agents for vp imaging  philip graham
Mr contrast agents for vp imaging philip graham
 
3rd vp symposium jang
3rd vp symposium jang3rd vp symposium jang
3rd vp symposium jang
 
083 non invasive imaging of the vulnerable plaque
083 non invasive imaging of  the vulnerable plaque083 non invasive imaging of  the vulnerable plaque
083 non invasive imaging of the vulnerable plaque
 
241 genetic influence on carotid atherosclerosis
241 genetic influence on carotid atherosclerosis241 genetic influence on carotid atherosclerosis
241 genetic influence on carotid atherosclerosis
 
Monocyte recruitment into atherosclerotic plaques
Monocyte recruitment into atherosclerotic plaquesMonocyte recruitment into atherosclerotic plaques
Monocyte recruitment into atherosclerotic plaques
 
179 chlamydophila pneumoniae
179 chlamydophila pneumoniae179 chlamydophila pneumoniae
179 chlamydophila pneumoniae
 
Basic molecular genetic studies in atherosclerosis
Basic molecular genetic studies in atherosclerosisBasic molecular genetic studies in atherosclerosis
Basic molecular genetic studies in atherosclerosis
 
144 physics of mri
144 physics of mri144 physics of mri
144 physics of mri
 
077 intravascular ultrasound for plaque characterization
077 intravascular ultrasound  for plaque characterization077 intravascular ultrasound  for plaque characterization
077 intravascular ultrasound for plaque characterization
 
Intravascular micro bolometer catheter thi
Intravascular micro bolometer catheter  thiIntravascular micro bolometer catheter  thi
Intravascular micro bolometer catheter thi
 
097 atherosclerotic lesions have regions of low p h
097 atherosclerotic lesions have regions of low p h097 atherosclerotic lesions have regions of low p h
097 atherosclerotic lesions have regions of low p h
 

Similar to Aeha muller 2

Dr. Alexander Parkhomenko. Utilidad de las nuevas técnicas de imagen invasivas
Dr. Alexander Parkhomenko. Utilidad de las nuevas técnicas de imagen invasivasDr. Alexander Parkhomenko. Utilidad de las nuevas técnicas de imagen invasivas
Dr. Alexander Parkhomenko. Utilidad de las nuevas técnicas de imagen invasivasSociedad Española de Cardiología
 
034 everybody has atherosclerosis
034 everybody has atherosclerosis034 everybody has atherosclerosis
034 everybody has atherosclerosisSHAPE Society
 
Site-specific intravascular ultrasound analysis of remodelling index and calc...
Site-specific intravascular ultrasound analysis of remodelling index and calc...Site-specific intravascular ultrasound analysis of remodelling index and calc...
Site-specific intravascular ultrasound analysis of remodelling index and calc...Cardiovascular Diagnosis and Therapy (CDT)
 
Coronary Ostial stenting techniques:Current status
Coronary Ostial stenting techniques:Current statusCoronary Ostial stenting techniques:Current status
Coronary Ostial stenting techniques:Current statusPawan Ola
 
magnetic resonance angiography
magnetic resonance angiographymagnetic resonance angiography
magnetic resonance angiographyqavi786
 
ARVD (Arrythmogenic right ventricular cardiomyopathy) - updated task force cr...
ARVD (Arrythmogenic right ventricular cardiomyopathy) - updated task force cr...ARVD (Arrythmogenic right ventricular cardiomyopathy) - updated task force cr...
ARVD (Arrythmogenic right ventricular cardiomyopathy) - updated task force cr...Imran Ahmed
 
Magnetic resonance angiography
Magnetic resonance angiographyMagnetic resonance angiography
Magnetic resonance angiographyRahman Ud Din
 

Similar to Aeha muller 2 (20)

Dr. Alexander Parkhomenko. Utilidad de las nuevas técnicas de imagen invasivas
Dr. Alexander Parkhomenko. Utilidad de las nuevas técnicas de imagen invasivasDr. Alexander Parkhomenko. Utilidad de las nuevas técnicas de imagen invasivas
Dr. Alexander Parkhomenko. Utilidad de las nuevas técnicas de imagen invasivas
 
034 everybody has atherosclerosis
034 everybody has atherosclerosis034 everybody has atherosclerosis
034 everybody has atherosclerosis
 
Mri spio
Mri spioMri spio
Mri spio
 
034 everybody has atherosclerosis
034 everybody has atherosclerosis034 everybody has atherosclerosis
034 everybody has atherosclerosis
 
Europace 2016 acosta
Europace 2016 acostaEuropace 2016 acosta
Europace 2016 acosta
 
Site-specific intravascular ultrasound analysis of remodelling index and calc...
Site-specific intravascular ultrasound analysis of remodelling index and calc...Site-specific intravascular ultrasound analysis of remodelling index and calc...
Site-specific intravascular ultrasound analysis of remodelling index and calc...
 
Carotid angioplasty
Carotid angioplastyCarotid angioplasty
Carotid angioplasty
 
carotid angioplasty
carotid angioplastycarotid angioplasty
carotid angioplasty
 
Coronary Ostial stenting techniques:Current status
Coronary Ostial stenting techniques:Current statusCoronary Ostial stenting techniques:Current status
Coronary Ostial stenting techniques:Current status
 
IVUS
IVUSIVUS
IVUS
 
magnetic resonance angiography
magnetic resonance angiographymagnetic resonance angiography
magnetic resonance angiography
 
163 infra redx
163 infra redx163 infra redx
163 infra redx
 
163 infra redx
163 infra redx163 infra redx
163 infra redx
 
Krucoff infra redx_aha_2002_x2
Krucoff infra redx_aha_2002_x2Krucoff infra redx_aha_2002_x2
Krucoff infra redx_aha_2002_x2
 
CALCIFIED CORONARY ARTERY LESIONS
CALCIFIED CORONARY ARTERY LESIONSCALCIFIED CORONARY ARTERY LESIONS
CALCIFIED CORONARY ARTERY LESIONS
 
ARVD (Arrythmogenic right ventricular cardiomyopathy) - updated task force cr...
ARVD (Arrythmogenic right ventricular cardiomyopathy) - updated task force cr...ARVD (Arrythmogenic right ventricular cardiomyopathy) - updated task force cr...
ARVD (Arrythmogenic right ventricular cardiomyopathy) - updated task force cr...
 
Multi-modal CT scanning in the evaluation of cerebrovascular disease patients
Multi-modal CT scanning in the evaluation of cerebrovascular disease patientsMulti-modal CT scanning in the evaluation of cerebrovascular disease patients
Multi-modal CT scanning in the evaluation of cerebrovascular disease patients
 
Definition of vulnerable plaque naghavi- thi
Definition of vulnerable plaque  naghavi- thiDefinition of vulnerable plaque  naghavi- thi
Definition of vulnerable plaque naghavi- thi
 
Pandemic of cvd atlanta
Pandemic of cvd atlantaPandemic of cvd atlanta
Pandemic of cvd atlanta
 
Magnetic resonance angiography
Magnetic resonance angiographyMagnetic resonance angiography
Magnetic resonance angiography
 

More from Society for Heart Attack Prevention and Eradication

More from Society for Heart Attack Prevention and Eradication (20)

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
 
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vu lplaque1 pasterkamp
 
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable patient mar 04
 
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln shape aha 2005
 
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vuln plaque poster burke
 
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25
 
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
 
Vp watch2002
Vp watch2002Vp watch2002
Vp watch2002
 
Vp symposium31602
Vp symposium31602Vp symposium31602
Vp symposium31602
 
Vpschoenhagen
VpschoenhagenVpschoenhagen
Vpschoenhagen
 
Vp meeting orlando2003_new template
Vp meeting orlando2003_new templateVp meeting orlando2003_new template
Vp meeting orlando2003_new template
 
Vpiii lobby-02
Vpiii lobby-02Vpiii lobby-02
Vpiii lobby-02
 
Vp
VpVp
Vp
 
Vp.org cimit harvard
Vp.org cimit harvardVp.org cimit harvard
Vp.org cimit harvard
 

Recently uploaded

The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...JakeMatthews12
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyYves Sucaet
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKQuick MedTalk
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedSBL DIGITAL
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedSBL DIGITAL
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)pranavguleria2
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxRajendra Dev Bhatt
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxAbdirahmanWaseem
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersSai Sailesh Kumar Goothy
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptxushakiranmai4
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, PDr.Shalu Jain
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Ahmad Thanin
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfMayuriGamit2
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdfHongBiThi1
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Dr. Dheeraj Kumar
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisAshishMaletha2
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfNetHelix
 

Recently uploaded (20)

The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathology
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
 
Oral disorders .pptx
Oral disorders .pptxOral disorders .pptx
Oral disorders .pptx
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limited
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptx
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disorders
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptx
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, P
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth Analysis
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdf
 

Aeha muller 2

  • 2. Clinical Identification of Vulnerable Patients and Plaques Screen the General Population By Conventional Risk Factors (Age, Gender, FH, etc) Vulnerable Patients by blood test Vulnerable Patients and ?Vulnerable Plaques by Non- invasive assessment Plaque Vulnerability Index by Invasive Assessment ACS and Stable Angina Patients
  • 3. “Soft Plaque” on Contrast-enhanced EBCT Dr. John Rumberger
  • 4. Non-invasive CT and MR for VP …. although there is much discussed on soft versus hard plaque – the characterization of any “soft” plaque as one that is potentially “vulnerable” remains moot. Dr. John Rumberger
  • 5. Presumably Vulnerable Plaques Discovered in 6 Autopsy Specimens
  • 6. Disrupted Coronary Artery Plaques in 6 Autopsy Specimens
  • 7. Prevalence of Thin-capped Fibroatheromas (TCFAs) and Disrupted Plaques in 50 Hearts Examined at Autopsy NUMBER OF HEARTS NUMBER OF TCFAs NUMBER OF DPs 32 0 0 4 1 0 2 1 1 3 2 0 1 2 3 1 3 0 1 3 1 1 4 0 1 5 3 4 1 0 From approximately 3000 slides, 0.5% showed DPs and 1 % TCFAs. Unpublished data, InfraRedx
  • 8. TCFA & DP Frequency Frequency of TCFAs & DPs in Individual Patients (N=50 patients & 3599 spots examined) 0 5 10 15 20 0 1 2 3 4 5 6 7 8 # TCFAs & DPs #Patients
  • 9. Thermography intravascular MR Optical Coherence Tomography Angioscopy Near IR Catheter-based Detection of Vulnerable Plaque IVUS, VH Elastog raphy JTS Nuclear
  • 10. Image Interpretation The Volcano IVUS Program • In-vivo characterization of plaque composition via advanced spectral analysis Pending 510(K) review – not available in the United States
  • 11. Volcano IVUS – Program Goals Re-Thinking IVUS… • Speeding the IVUS procedure • Improving ease of image interpretation • Improving consistency of image interpretation • Understanding benefit of more information on plaque composition – during PCI – for risk stratifying lesions and patients Pending 510(K) review – not available in the United States
  • 12. Volcano IVUS – Confirming Feasibility in a Clinical Setting Repeatability / Reproducibility (J. Margolis, Miami) Miami_AA_ROI1_RCA1 0 0.5 1 1.5 2 2.5 3 3.5 4 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 Frame NumberCSA(mm^2) Lipid Core Cross-Sectional Area Fibro-Lipidic Cross-Sectional Area Fibrous Cross-Sectional Area Calcified Cross-Sectional Area Distal Proximal Miami_AA_ROI1_RCA2 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 Frame Number CSA(mm^2) Lipid Core Cross-Sectional Area Fibro-Lipidic Cross-Sectional Area Fibrous Cross-Sectional Area Calcified Cross-Sectional Area Distal Proximal 1st Pull-Back Same Catheter, 2nd Pull-Back One catheter, two runs Pending 510(K) review – not available in the United States
  • 13.   SOFT HARD IVUS-based Intravascular Palpography Investigational Use Only – Not Available for Sale in the United States
  • 14. Temperature heterogeneity over the surface of an endartherectomized carotid plaque Casscells W et al. Lancet. 1996;347:1447-51
  • 15. OCT of Disrupted CoronaryPlaque in a Living Patient MI Rupture Site, In Vivo C L L L Jang, Bouma, Tearney et al, CIMIT
  • 16. Intravascular MRI CatheterIntravascular MRI Catheter NC NCMagnet Coil Luminal Zone Mural Zone  Catheter based real-time MRI - No external magnets  High sensitivity & specificity for differentiating:  Fibrous tissue  Lipid rich necrotic core  Calcium  Thrombus (next generation) Virmani et al, JACC 2004 (Submitted) Presented by RL Wilensky @ TCT 2004 Over 18 patients studied by Dr. Hennen – No AE
  • 17. NIR Spectroscopy for VP Detection • NIR spectroscopy is a well-validated method frequently used to assess chemical composition. • Laser, fiber-optic, and chemometric technologies make intra-coronary use feasible. • 3.2Fr IVUS-like rapid-exchange coronary catheter • Can scan artery through blood • 20 msec spectra acquisition • Identifies chemical composition of vessel wall – TCFA sensitivity and specificity > 85% ex vivo – TCFA surrogates detected in phantom
  • 18. Natural History Study of Detection Vulnerable Plaque 1000 patients with ACS undergoing PTCA/ Stenting Vulnerability Detector 100 Patients with suspected VP 900 Patients without suspectedV P 1 yr F.U. MI SCD
  • 19. Prospect StudyProspect Study PI, Dr. Gregg StonePI, Dr. Gregg Stone Guidant, VolcanoGuidant, Volcano 3-vessel imaging post PCI3-vessel imaging post PCI Angiography (QCA of entire coronary tree)Angiography (QCA of entire coronary tree) IVUSIVUS Virtual histologyVirtual histology PalpographyPalpography ± Thermography (EU only)± Thermography (EU only) F/U: 1 mo, 6 mo, 1 yrF/U: 1 mo, 6 mo, 1 yr 2 yr,2 yr, ±±3-5 yr3-5 yr (event driven)(event driven) Repeat imagingRepeat imaging in pts with eventsin pts with events Meds recMeds rec AspirinAspirin Plavix 1yrPlavix 1yr StatinStatin
  • 20. 1-year MACE (adjudicated to non-culprit lsn)1-year MACE (adjudicated to non-culprit lsn) -- Cardiac deathCardiac death -- Cardiac arrestCardiac arrest -- Rehospitalization for ACSRehospitalization for ACS -- Myocardial infarctionMyocardial infarction -- Clinically driven revascularizationClinically driven revascularization Procedural Success and Imaging SafetyProcedural Success and Imaging Safety Ability to complete the protocol-specifiedAbility to complete the protocol-specified imaging procedures w/o imaging deviceimaging procedures w/o imaging device related complicationsrelated complications PROSPECT:PROSPECT: Primary endpointsPrimary endpoints
  • 21. 1 year Follow-up for Cardiac Events: MI, SCD, UA Vulnerability Map of the Human Coronary Artery

Editor's Notes

  1. Volcano is also developing advanced tissue characterization software, to ease image interpretation and give more information about the composition of atherosclerotic plaques. This technology, licensed from The Cleveland Clinic Foundation, is based on over 8 years of intensive development. This sophisticated software algorithm uses spectral analysis of the ultrasound frequency (rather than just the amplitude – or power, as is used for grayscale IVUS) of the returning sound wave to predict composition of plaques. Thus, instead of the physician being asked to interpret highly subjective images based on 256 shades of gray, interpretation is simplified with presentation of the most commonly found tissue types in just 4 colors on screen.
  2. Volcano’s next generation of IVUS reflects our mission to “Re-Think” IVUS – making it faster, easier to interpret, with more information from the images and data.
  3. Repeatability studies have been run in Miami to assess variability, from one catheter run to the next in the same patient…
  4. Volcano recently secured a world-wide exclusive license to technology out of Rotterdam, The Netherlands, called palpography. This technology, which uses the very same raw RF data that we use to do VH, essentially allows for an estimation of the stiffness of the inside of an artery. This really clever technology, which has been built around the Avanar / Eagle Eye catheters, uses the native changes in blood pressure during coronary cycle to essentially “palpate” the inner lumen of the vessel. It then highlights the interface between “stiff” and “squishy” segments of the vessel wall. It is hypothesized that it is at this interface between stiff and squishy that you have the fibrous caps vulnerable to rupture. Again, the unique aspect of this technology is that we believe we can collect this data and display the findings real time, all from the same catheter and on the same pull-back.